Beacon Therapeutics

Ophthalmic gene therapy company developing treatments for inherited and prevalent retinal diseases causing vision loss, including X-linked retinitis pigmentosa and dry age-related macular degeneration; has raised approximately $290 million including a $170 million Series B in 2024.